In subgroup III, CDK4 amplification and PRKDC amplification jointly promoted increased CDK4 protein expression and kinase activity in melanoma patients, accelerating the proliferation rate of melanoma and leading to poor prognosis. The gene discussed is CDK4; the disease is melanoma.